AC133-specific CAR T cells

AC133-specific CAR T cells are an investigational cell therapy in which a patient’s T cells are genetically engineered to express a chimeric antigen receptor (CAR) that specifically recognizes the AC133 epitope on CD133, a cell surface marker enriched on cancer stem cells in various tumors including glioblastoma multiforme and small cell lung cancer. These CAR T cells are designed to target and kill chemo-resistant and tumor-initiating cells expressing the AC133 epitope, deliverying cytotoxic activity specifically to cancer stem cell populations. Preclinical studies have shown that AC133-specific CAR T cells can recognize and eliminate AC133+ tumor cells in both in vitro and in vivo models, prolonging survival in animal models of glioblastoma and small cell lung cancer. The therapy uses a third-generation CAR construct with an AC133-specific single chain antibody fragment (scFv) linked to co-stimulatory and activation domains (such as CD28, 4-1BB, and CD3 zeta). This approach aims to overcome relapse in cancer by eradicating resistant cancer stem cells. The therapy is in preclinical and early clinical investigation, with additional interest in combining it with immune checkpoint and CD73 inhibitors to enhance efficacy against immune-escape mechanisms.

Other names

AC133-CAR T cellsAC-133-CAR T cellsAC 133-CAR T cellsAC133-targeted CAR T cellsAC-133-targeted CAR T cellsAC 133-targeted CAR T cells